Chemical: Drug
methylphenidate

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for methylphenidate

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *5 N/A N/A N/A
No VIP available CA VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 extensive metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1044396 NC_000020.10:g.61981134G>A, NC_000020.11:g.63349782G>A, NG_011931.1:g.16562C>T, NM_000744.6:c.1629C>T, NM_001256573.1:c.1101C>T, NP_000735.1:p.Ser543=, NP_001243502.1:p.Ser367=, NR_046317.1:n.1885C>T, XM_005260189.1:c.1416C>T, XM_005260190.1:c.1101C>T, XM_005260191.1:c.1101C>T, XM_011528524.1:c.1416C>T, XP_005260246.1:p.Ser472=, XP_005260247.1:p.Ser367=, XP_005260248.1:p.Ser367=, XP_011526826.1:p.Ser472=, rs3184143, rs3746385
G > -
G > A
SNP
S543S
No VIP available No Clinical Annotations available VA
rs11134178 NC_000005.10:g.6834054T>C, NC_000005.9:g.6834167T>C, rs60818519
T > C
SNP
No VIP available No Clinical Annotations available VA
rs11246226 NC_000011.10:g.641191C=, NC_000011.10:g.641191C>A, NC_000011.9:g.641191C>A, NG_021241.1:g.8887C=, NG_021241.1:g.8887C>A, NM_000797.3:c.*103+485C>A, NM_000797.3:c.*588A>C, NM_000797.3:c.*588C>A, NT_187586.1:g.171060A=, NT_187586.1:g.171060A>C, rs58546708
C > A
SNP
No VIP available No Clinical Annotations available VA
rs11568817 NC_000006.11:g.78173382A>C, NC_000006.12:g.77463665A>C, NM_000863.2:c.-262T>G, XR_942706.1:n.545-10861A>C, XR_942707.1:n.545-10861A>C, XR_942708.1:n.545-10861A>C, XR_942709.1:n.545-10861A>C
A > C
SNP
No VIP available No Clinical Annotations available VA
rs12443580 NC_000016.10:g.55832425T>C, NC_000016.9:g.55866337T>C, NG_012057.1:g.5739A>G, NM_001025194.1:c.52+579A>G, NM_001025195.1:c.52+579A>G, NM_001266.4:c.52+579A>G, NW_003315945.1:g.56329T>C, XM_005255774.1:c.52+579A>G, XM_005276867.1:c.52+580A>G, XM_011522816.1:c.52+579A>G, XM_011546995.1:c.52+580A>G, rs58785036
T > C
SNP
No VIP available No Clinical Annotations available VA
rs13212041 NC_000006.11:g.78171124C>T, NC_000006.12:g.77461407C>T, NM_000863.2:c.*824G>A, XR_942706.1:n.545-13119C>T, XR_942707.1:n.545-13119C>T, XR_942708.1:n.545-13119C>T, XR_942709.1:n.545-13119C>T
C > T
SNP
No VIP available CA VA
rs1355368 NC_000004.11:g.62779822A>G, NC_000004.12:g.61914104A>G, NG_033950.1:g.421984A>G, NM_015236.4:c.1908+1347A>G, NW_003315916.1:g.23912A>G, XM_005265660.1:c.2112+1347A>G, XM_005265661.1:c.1908+1347A>G, XM_011531784.1:c.2097+1347A>G, XM_011531785.1:c.2097+1347A>G, XM_011531786.1:c.2112+1347A>G, XM_011531787.1:c.2073+4359A>G, XM_011531788.1:c.2112+1347A>G, XM_011531789.1:c.2112+1347A>G, XM_011531790.1:c.2112+1347A>G, XM_011531791.1:c.2073+4359A>G, XM_011531792.1:c.1908+1347A>G, XM_011531793.1:c.2112+1347A>G, rs52817664
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1611115 NC_000009.11:g.136500515T>C, NC_000009.12:g.133635393T>C, NG_008645.1:g.4031T>C, NM_000787.3:c.-979T>C, rs60944937
T > C
SNP
No VIP available CA VA
rs1800544 NC_000010.10:g.112836503G>C, NC_000010.11:g.111076745G>C, NG_012020.1:g.4714G>C, NM_000681.3:c.-1252G>C
G > C
SNP
No VIP available No Clinical Annotations available VA
rs1843809 NC_000012.11:g.72348698G>T, NC_000012.12:g.71954918G>T, NG_008279.1:g.21073G>T, NM_173353.3:c.608+5263G>T, XM_005268642.1:c.626+5263G>T, XM_011537899.1:c.14+5263G>T, XR_245894.1:n.612+5263G>T, XR_245894.2:n.708+5263G>T, rs61293102
G > T
SNP
No VIP available CA VA
rs1947275 NC_000004.11:g.62744545T>C, NC_000004.12:g.61878827T>C, NG_033950.1:g.386707T>C, NM_015236.4:c.1277-13829T>C, XM_005265660.1:c.1481-13829T>C, XM_005265661.1:c.1277-13829T>C, XM_011531784.1:c.1466-13829T>C, XM_011531785.1:c.1481-13844T>C, XM_011531786.1:c.1481-13829T>C, XM_011531787.1:c.1481-13829T>C, XM_011531788.1:c.1481-13829T>C, XM_011531789.1:c.1481-13829T>C, XM_011531790.1:c.1481-13829T>C, XM_011531791.1:c.1481-13829T>C, XM_011531792.1:c.1277-13829T>C, XM_011531793.1:c.1481-13829T>C, rs17239171, rs60568734, rs60821071
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2002577 NC_000016.10:g.55815590G>C, NC_000016.9:g.55849502G>C, NG_012057.1:g.22574C>G, NM_001025194.1:c.942+1334C>G, NM_001025195.1:c.945+1334C>G, NM_001266.4:c.942+1334C>G, NW_003315945.1:g.39468G>C, XM_005255774.1:c.945+1334C>G, XM_005276867.1:c.945+1334C>G, XM_011522816.1:c.945+1334C>G, XM_011546995.1:c.945+1334C>G, rs16956424
G > C
G > T
SNP
No VIP available No Clinical Annotations available VA
rs2242446 NC_000016.10:g.55656513C>T, NC_000016.9:g.55690425C>T, NG_016969.1:g.5884C>T, NM_001043.3:c.-182C>T, NM_001172501.1:c.-51-131C>T, NM_001172504.1:c.-182C>T, XM_006721263.2:c.-51-131C>T, XM_011523295.1:c.-51-131C>T, XM_011523296.1:c.-51-131C>T, XM_011523297.1:c.-51-131C>T, XM_011523298.1:c.-51-131C>T, XR_933403.1:n.567-131C>T, XR_933603.1:n.-861G>A, rs59199002
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2244613 NC_000016.10:g.55810697G>T, NC_000016.9:g.55844609G>T, NG_012057.1:g.27467C>A, NM_001025194.1:c.1168-33C>A, NM_001025195.1:c.1171-33C>A, NM_001266.4:c.1165-33C>A, NW_003315945.1:g.34574G>T, XM_005255774.1:c.1168-33C>A, XM_005276867.1:c.1168-33C>A, rs61164855, rs72486000
G > T
SNP
No VIP available No Clinical Annotations available VA
rs2287194
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2307240 NC_000016.10:g.55828800C>T, NC_000016.9:g.55862712C>T, NG_012057.1:g.9364G>A, NM_001025194.1:c.224G>A, NM_001025195.1:c.227G>A, NM_001266.4:c.224G>A, NP_001020365.1:p.Ser75Asn, NP_001020366.1:p.Ser76Asn, NP_001257.4:p.Ser75Asn, NW_003315945.1:g.52681C>T, XM_005255774.1:c.227G>A, XM_005276867.1:c.227G>A, XM_011522816.1:c.227G>A, XM_011546995.1:c.227G>A, XP_005255831.1:p.Ser76Asn, XP_005276924.1:p.Ser76Asn, XP_011521118.1:p.Ser76Asn, XP_011545297.1:p.Ser76Asn, rs52810343
C > T
SNP
S75N
No VIP available No Clinical Annotations available VA
rs2307244
G > A
SNP
No VIP available No Clinical Annotations available VA
rs363020 NC_000020.10:g.10237223T>A, NC_000020.11:g.10256575T>A, NG_029626.1:g.42747T>A, NM_003081.3:c.-63-18854T>A, NM_130811.2:c.-63-18854T>A, XM_005260808.1:c.-63-18854T>A, XM_005260808.3:c.-63-18854T>A, XM_005260809.1:c.-63-18854T>A, XM_005260810.1:c.-63-18854T>A, XM_005260810.3:c.-63-18854T>A, XM_005260811.1:c.-63-18854T>A, XM_005260812.1:c.-370-18854T>A, rs17441216, rs56450660, rs60673004
T > A
SNP
No VIP available No Clinical Annotations available VA
rs3746544 NC_000020.10:g.10287084G>T, NC_000020.11:g.10306436G>T, NG_029626.1:g.92608G>T, NM_003081.3:c.*239G>T, NM_130811.2:c.*239G>T, XM_005260808.1:c.*239G>T, XM_005260808.3:c.*239G>T, XM_005260809.1:c.*239G>T, XM_005260810.1:c.*239G>T, XM_005260810.3:c.*239G>T, XM_005260811.1:c.*239G>T, XM_005260812.1:c.*239G>T, rs17521224
G > T
SNP
No VIP available No Clinical Annotations available VA
rs3815583 NC_000016.10:g.55833130A=, NC_000016.10:g.55833130A>C, NC_000016.9:g.55867042A=, NC_000016.9:g.55867042A>C, NG_012057.1:g.5034T=, NG_012057.1:g.5034T>G, NM_001025194.1:c.-75T=, NM_001025194.1:c.-75T>G, NM_001025195.1:c.-75T=, NM_001025195.1:c.-75T>G, NM_001266.4:c.-75T=, NM_001266.4:c.-75T>G, NW_003315945.1:g.57035C=, NW_003315945.1:g.57035C>A, XM_005255774.1:c.-75T=, XM_005255774.1:c.-75T>G, XM_005276867.1:c.-75G=, XM_005276867.1:c.-75G>T, XM_011522816.1:c.-75T=, XM_011522816.1:c.-75T>G, XM_011546995.1:c.-75G=, XM_011546995.1:c.-75G>T, rs11076115, rs118051681
A > C
SNP
No VIP available No Clinical Annotations available VA
rs3815589
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3836790 NC_000005.10:g.1411740_1411741insCACATACCATGCAACATACACACTCAGACA, NC_000005.9:g.1411855_1411856insCACATACCATGCAACATACACACTCAGACA, NG_015885.1:g.38688_38689insTGTCTGAGTGTGTATGTTGCATGGTATGTG, NM_001044.4:c.1157-386_1157-385insTGTCTGAGTGTGTATGTTGCATGGTATGTG, NT_187547.1:g.102268_102269insTGTCTGAGTGTGTATGTTGCATGGTATGTG
- > CACATACCATGCAACATACACACTCAGACA
indel
No VIP available CA VA
rs4532 NC_000005.10:g.175443147C>T, NC_000005.9:g.174870150C>T, NG_011802.1:g.6014G>A, NM_000794.3:c.-48G>A, rs1310294, rs265980, rs61505681
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4570625 NC_000012.11:g.72331923G>T, NC_000012.12:g.71938143G>T, NG_008279.1:g.4298G>T, NM_173353.3:c.-844G>T, XM_005268642.1:c.-844G>T, XR_245894.1:n.-840G>T, XR_245894.2:n.-744G>T, rs60080807
G > T
SNP
No VIP available No Clinical Annotations available VA
rs4680 NC_000022.10:g.19951271G>A, NC_000022.11:g.19963748G>A, NG_011526.1:g.27009G>A, NM_000754.3:c.472G>A, NM_001135161.1:c.472G>A, NM_001135162.1:c.472G>A, NM_007310.2:c.322G>A, NP_000745.1:p.Val158Met, NP_001128633.1:p.Val158Met, NP_001128634.1:p.Val158Met, NP_009294.1:p.Val108Met, NR_039918.1:n.-5G>A, XM_005261229.1:c.472G>A, XM_011529885.1:c.586G>A, XM_011529886.1:c.586G>A, XM_011529887.1:c.472G>A, XM_011529888.1:c.472G>A, XM_011529889.1:c.472G>A, XM_011529890.1:c.472G>A, XM_011529891.1:c.472G>A, XP_005261286.1:p.Val158Met, XP_011528187.1:p.Val196Met, XP_011528188.1:p.Val196Met, XP_011528189.1:p.Val158Met, XP_011528190.1:p.Val158Met, XP_011528191.1:p.Val158Met, XP_011528192.1:p.Val158Met, XP_011528193.1:p.Val158Met, rs1131157, rs11544671, rs165688, rs17295216, rs17349704, rs17818178, rs17849308, rs17850006, rs2070104, rs3177905, rs3190784, rs3747070, rs58002978
G > A
SNP
V158M
No VIP available No Clinical Annotations available VA
rs4867798 NC_000005.10:g.175440896T>C, NC_000005.9:g.174867899T>C, NG_011802.1:g.8265A>G, NM_000794.3:c.*863A>G, rs59650206
T > C
SNP
No VIP available No Clinical Annotations available VA
rs5326 NC_000005.10:g.175443193C>T, NC_000005.9:g.174870196C>T, NG_011802.1:g.5968G>A, NM_000794.3:c.-94G>A, rs59257322
C > T
SNP
No VIP available No Clinical Annotations available VA
rs5568 NC_000016.10:g.55696212A>C, NC_000016.9:g.55730124A>C, NG_016969.1:g.45583A>C, NM_001043.3:c.1148-13A>C, NM_001172501.1:c.1148-13A>C, NM_001172502.1:c.833-13A>C, NM_001172504.1:c.1148-13A>C, XM_006721263.2:c.1148-13A>C, XM_011523295.1:c.1148-13A>C, XM_011523296.1:c.1013-13A>C, XM_011523297.1:c.1013-13A>C, XM_011523298.1:c.1147+810A>C, XM_011523299.1:c.425-13A>C, XM_011523300.1:c.425-13A>C, XR_933403.1:n.1765-13A>C, rs1122349, rs17308668, rs57905851
A > C
SNP
No VIP available CA VA
rs5569 NC_000016.10:g.55697923G>A, NC_000016.9:g.55731835G>A, NG_016969.1:g.47294G>A, NM_001043.3:c.1287G>A, NM_001172501.1:c.1287G>A, NM_001172502.1:c.972G>A, NM_001172504.1:c.1287G>A, NP_001034.1:p.Thr429=, NP_001165972.1:p.Thr429=, NP_001165973.1:p.Thr324=, NP_001165975.1:p.Thr429=, XM_006721263.2:c.1287G>A, XM_011523295.1:c.1287G>A, XM_011523296.1:c.1152G>A, XM_011523297.1:c.1152G>A, XM_011523298.1:c.1174G>A, XM_011523299.1:c.564G>A, XM_011523300.1:c.564G>A, XP_006721326.1:p.Thr429=, XP_011521597.1:p.Thr429=, XP_011521598.1:p.Thr384=, XP_011521599.1:p.Thr384=, XP_011521600.1:p.Gly392Arg, XP_011521601.1:p.Thr188=, XP_011521602.1:p.Thr188=, XR_933403.1:n.1904G>A, rs17308809, rs386599040, rs59357911, rs998425
G > A
SNP
T429T
No VIP available No Clinical Annotations available VA
rs6090384 NC_000020.10:g.61990874T>C, NC_000020.11:g.63359522T>C, NG_011931.1:g.6822A>G, NM_000744.6:c.228+26A>G, NM_001256573.1:c.-319+26A>G, NR_046317.1:n.459+26A>G, NR_110634.1:n.-466T>C, XM_005260189.1:c.-86+26A>G, XM_005260190.1:c.-145-8495A>G, XR_244127.1:n.-466T>C, rs60741015
T > C
SNP
No VIP available CA VA
rs6280 NC_000003.11:g.113890815C>T, NC_000003.12:g.114171968C>T, NG_008842.2:g.32440G>A, NM_000796.5:c.25G>A, NM_001282563.2:c.25G>A, NM_001290809.1:c.25G>A, NM_033663.5:c.25G>A, NP_000787.2:p.Gly9Ser, NP_001269492.1:p.Gly9Ser, NP_001277738.1:p.Gly9Ser, NP_387512.3:p.Gly9Ser, XM_005247170.1:c.25G>A, XM_005247171.1:c.25G>A, XM_011512510.1:c.25G>A, XM_011512511.1:c.25G>A, XM_011512512.1:c.25G>A, XP_005247227.1:p.Gly9Ser, XP_005247228.1:p.Gly9Ser, XP_011510812.1:p.Gly9Ser, XP_011510813.1:p.Gly9Ser, XP_011510814.1:p.Gly9Ser, rs117481259, rs324025, rs52792556, rs59703514
C > T
SNP
G9S
No VIP available No Clinical Annotations available VA
rs6296 NC_000006.11:g.78172260C>G, NC_000006.12:g.77462543C>G, NM_000863.2:c.861G>C, NP_000854.1:p.Val287=, XR_942706.1:n.545-11983C>G, XR_942707.1:n.545-11983C>G, XR_942708.1:n.545-11983C>G, XR_942709.1:n.545-11983C>G, rs3748086, rs61223995
C > G
SNP
V287V
No VIP available CA VA
rs6551665 NC_000004.11:g.62739541G>A, NC_000004.12:g.61873823G>A, NG_033950.1:g.381703G>A, NM_015236.4:c.1277-18833G>A, XM_005265660.1:c.1481-18833G>A, XM_005265661.1:c.1277-18833G>A, XM_011531784.1:c.1466-18833G>A, XM_011531785.1:c.1481-18848G>A, XM_011531786.1:c.1481-18833G>A, XM_011531787.1:c.1481-18833G>A, XM_011531788.1:c.1481-18833G>A, XM_011531789.1:c.1481-18833G>A, XM_011531790.1:c.1481-18833G>A, XM_011531791.1:c.1481-18833G>A, XM_011531792.1:c.1277-18833G>A, XM_011531793.1:c.1481-18833G>A, rs58013318
G > A
SNP
No VIP available CA VA
rs6813183 NC_000004.11:g.62769131G>C, NC_000004.12:g.61903413G>C, NG_033950.1:g.411293G>C, NM_015236.4:c.1684-6147G>C, XM_005265660.1:c.1888-6147G>C, XM_005265661.1:c.1684-6147G>C, XM_011531784.1:c.1873-6147G>C, XM_011531785.1:c.1873-6147G>C, XM_011531786.1:c.1888-6147G>C, XM_011531787.1:c.1888-6147G>C, XM_011531788.1:c.1888-6147G>C, XM_011531789.1:c.1888-6147G>C, XM_011531790.1:c.1888-6147G>C, XM_011531791.1:c.1888-6147G>C, XM_011531792.1:c.1684-6147G>C, XM_011531793.1:c.1888-6147G>C, rs60557652
G > C
SNP
No VIP available CA VA
rs71647871 NC_000016.10:g.55823658C>T, NC_000016.9:g.55857570C>T, NG_012057.1:g.14506G>A, NM_001025194.1:c.428G>A, NM_001025195.1:c.431G>A, NM_001266.4:c.428G>A, NP_001020365.1:p.Gly143Glu, NP_001020366.1:p.Gly144Glu, NP_001257.4:p.Gly143Glu, NW_003315945.1:g.47536C>T, XM_005255774.1:c.431G>A, XM_005276867.1:c.431G>A, XM_011522816.1:c.431G>A, XM_011546995.1:c.431G>A, XP_005255831.1:p.Gly144Glu, XP_005276924.1:p.Gly144Glu, XP_011521118.1:p.Gly144Glu, XP_011545297.1:p.Gly144Glu
C > T
SNP
G143E
No VIP available No Clinical Annotations available VA
rs71647872
T > -
indel
No VIP available CA VA
rs734644 NC_000004.11:g.62800728T>C, NC_000004.12:g.61935010T>C, NG_033950.1:g.442890T>C, NM_015236.4:c.2079T>C, NP_056051.2:p.Asn693=, NW_003315916.1:g.44819T>C, XM_005265660.1:c.2283T>C, XM_005265661.1:c.2079T>C, XM_011531784.1:c.2268T>C, XM_011531785.1:c.2268T>C, XM_011531786.1:c.2283T>C, XM_011531787.1:c.2244T>C, XM_011531788.1:c.2283T>C, XM_011531789.1:c.2283T>C, XM_011531790.1:c.2283T>C, XM_011531791.1:c.2244T>C, XM_011531792.1:c.2079T>C, XM_011531793.1:c.2283T>C, XP_005265717.1:p.Asn761=, XP_005265718.1:p.Asn693=, XP_011530086.1:p.Asn756=, XP_011530087.1:p.Asn756=, XP_011530088.1:p.Asn761=, XP_011530089.1:p.Asn748=, XP_011530090.1:p.Asn761=, XP_011530091.1:p.Asn761=, XP_011530092.1:p.Asn761=, XP_011530093.1:p.Asn748=, XP_011530094.1:p.Asn693=, XP_011530095.1:p.Asn761=, rs17226328, rs61382511
T > C
SNP
N693N
No VIP available No Clinical Annotations available VA
rs828199 NC_000013.10:g.91370838T>C, NC_000013.11:g.90718584T>C, rs1041254, rs1616905
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9627183 NC_000022.10:g.48284514G>A, NC_000022.11:g.47888765G>A, rs59941747
G > A
SNP
No VIP available No Clinical Annotations available VA
rs998424 NC_000016.10:g.55698034G>A, NC_000016.9:g.55731946G>A, NG_016969.1:g.47405G>A, NM_001043.3:c.1389+9G>A, NM_001172501.1:c.1389+9G>A, NM_001172502.1:c.1074+9G>A, NM_001172504.1:c.1389+9G>A, XM_006721263.2:c.1389+9G>A, XM_011523295.1:c.1389+9G>A, XM_011523296.1:c.1254+9G>A, XM_011523297.1:c.1254+9G>A, XM_011523298.1:c.*97G>A, XM_011523299.1:c.666+9G>A, XM_011523300.1:c.666+9G>A, XR_933403.1:n.2006+9G>A, rs13306044, rs1800886
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Methyl phenidyl acetate
  • Methylphenidate HCl
  • Methylphenidate hydrochloride
  • Methylphenidatum [INN-Latin]
  • Methylphenidylacetate hydrochloride
  • Metilfenidat hydrochloride
  • Metilfenidato [INN-Spanish]
  • Metilfenidato [Italian]
  • Phenidylate
  • d-methylphenidate HCl
  • methylphenidate
Trade Names
  • 4311/B Ciba
  • Calocain
  • Centedein
  • Centedrin
  • Centedrine
  • Centredin
  • Concerta
  • Daytrana
  • Focalin
  • Focalin XR
  • Meridil
  • Metadate
  • Metadate CD
  • Metadate ER
  • Methylin
  • Methylin ER
  • Methylofenidan
  • Methylphen
  • Methylphenidan
  • Methypatch
  • PMS-Methylphenidate
  • Plimasine
  • Riphenidate
  • Ritalin
  • Ritalin LA
  • Ritalin SR
  • Ritalin hydrochloride
  • Ritalin-SR
  • Ritaline
  • Ritcher Works
Brand Mixture Names

PharmGKB Accession Id

PA450464

Type(s):

Drug

Description

A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Source: Drug Bank

Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.

Source: Drug Bank

Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take on empty stomach: 1 hour before or 2 hours after meals.|Avoid excessive quantities of coffee or tea (Caffeine).

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (alpha-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.

Source: Drug Bank

Protein Binding

Low (approximately 15%)

Source: Drug Bank

Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Source: Drug Bank

Half-Life

2.4 hours in children and 2.1 hours in adults

Source: Drug Bank

Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD 50=190mg/kg (orally in mice)

Source: Drug Bank

Chemical Properties

Chemical Formula

C14H19NO2

Source: Drug Bank

Isomeric SMILES

COC(=O)C(c1ccccc1)C2CCCCN2

Source: OpenEye

Canonical SMILES

COC(=O)C(C1CCCCN1)C1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

233.3062

Source: Drug Bank

Monoisotopic Molecular Weight

233.141578857

Source: Drug Bank

SMILES

COC(=O)C(C1CCCCN1)C1=CC=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
SLC6A2 (source: Drug Bank)
SLC6A3 (source: Drug Bank)
SLC6A4 (source: Drug Bank)

Drug Interactions

Interaction Description
carbamazepine - methylphenidate Carbamazepine could reduce the effect of methylphenidate (source: Drug Bank)
carbamazepine - methylphenidate Carbamazepine could reduce the effect of methylphenidate (source: Drug Bank)
cyclosporine - methylphenidate Methylphenidate increases the effect and toxicity of cyclosporine (source: Drug Bank)
cyclosporine - methylphenidate Methylphenidate increases the effect and toxicity of cyclosporine (source: Drug Bank)
guanethidine - methylphenidate The agent decreases the effect of guanethidine (source: Drug Bank)
guanethidine - methylphenidate Methylphenidate may decrease the effect of guanethidine. (source: Drug Bank)
isocarboxazid - methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
isocarboxazid - methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - carbamazepine Carbamazepine could reduce the effect of methylphendiate (source: Drug Bank)
methylphenidate - carbamazepine Carbamazepine could reduce the effect of methylphendiate (source: Drug Bank)
methylphenidate - cyclosporine Methylphenidate increases the effect and toxicity of cyclosporine (source: Drug Bank)
methylphenidate - cyclosporine Methylphenidate increases the effect and toxicity of cyclosporine (source: Drug Bank)
methylphenidate - guanethidine The agent decreases the effect of guanethidine (source: Drug Bank)
methylphenidate - guanethidine Methylphenidate may decrease the effect of guanethidine. (source: Drug Bank)
methylphenidate - isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - phenelzine Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - phenelzine Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - rasagiline Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - tranylcypromine Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate - tranylcypromine Possible hypertensive crisis with this combination (source: Drug Bank)
phenelzine - methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
phenelzine - methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
rasagiline - methylphenidate Possible severe adverse reaction with this combination (source: Drug Bank)
trandolapril - methylphenidate Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed. (source: Drug Bank)
tranylcypromine - methylphenidate The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to methylphenidate: 34

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. Journal of neural transmission (Vienna, Austria : 1996). 2016. Hegvik Tor-Arne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. Genes, brain, and behavior. 2015. Bruxel E M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. Brain : a journal of neurology. 2015. Moreau Caroline, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics. 2015. Rasmussen Henrik Berg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug metabolism and drug interactions. 2014. Merali Zahra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective. Pharmacogenomics. 2014. Rovaris Diego L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. Journal of child and adolescent psychopharmacology. 2013. Johnson Katherine A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review. The Psychiatric quarterly. 2013. Patel Bianca D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology. 2013. Levy Florence, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. The pharmacogenomics journal. 2013. McCracken J T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. Journal of clinical psychopharmacology. 2013. Kim Bung-Nyun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. Journal of clinical psychopharmacology. 2012. Contini Verônica, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report. Pharmacogenomics and personalized medicine. 2013. Tan-Kam Teerarat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Improvement of glycemic control using methylphenidate treatment of apathy: a preliminary report. Journal of the American Geriatrics Society. 2012. Padala Prasad R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. The pharmacogenomics journal. 2012. Bruxel E M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. European journal of clinical pharmacology. 2011. Russo Roberta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry research. 2011. Lee Sung Hee, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. International clinical psychopharmacology. 2011. Song Jungeun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011. Meyer Markus R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional analysis of intron 8 and 3' UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants. The pharmacogenomics journal. 2010. Hill M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010. Kieling Christian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009. Nemoda Zsofia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common haplotype at the dopamine transporter gene 5' region is associated with attention-deficit/hyperactivity disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2008. Genro Júlia P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2008. Mick Eric, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. American journal of human genetics. 2008. Zhu Hao-Jie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2008. Tharoor Hema, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer. Journal of clinical psychopharmacology. 2007. Reimers Arne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of methylphenidate response in preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry. 2006. McGough James, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Potential interactions of methylphenidate and atomoxetine with dextromethorphan. Journal of the American Pharmacists Association : JAPhA. 2006. Ciccone Patrick E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse (New York, N.Y.). 2003. Rohde Luis A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics. 2002. Roman Tatiana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. Journal of clinical psychopharmacology. 2000. DeVane C L, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
54092-552-30
DrugBank:
DB00422
ChEBI:
6887
KEGG Compound:
C07196
KEGG Drug:
D04999
PubChem Compound:
4158
PubChem Substance:
46505929
Drugs Product Database (DPD):
2249332
ChemSpider:
4015
Therapeutic Targets Database:
DAP000024
FDA Drug Label at DailyMed:
12a36e92-cb00-48d5-8981-89d8cce8c4c6

Clinical Trials

These are trials that mention methylphenidate and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.